PMID- 27793569
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20210105
IS  - 1471-4981 (Electronic)
IS  - 1471-4906 (Print)
IS  - 1471-4906 (Linking)
VI  - 37
IP  - 12
DP  - 2016 Dec
TI  - Dendritic Cells and Cancer Immunity.
PG  - 855-865
LID - S1471-4906(16)30140-5 [pii]
LID - 10.1016/j.it.2016.09.006 [doi]
AB  - Dendritic cells (DCs) are central regulators of the adaptive immune response, and 
      as such are necessary for T-cell-mediated cancer immunity. In particular, 
      antitumoral responses depend on a specialized subset of conventional DCs that 
      transport tumor antigens to draining lymph nodes and cross-present antigen to 
      activate cytotoxic T lymphocytes. DC maturation is necessary to provide 
      costimulatory signals to T cells, but while DC maturation occurs within tumors, 
      it is often insufficient to induce potent immunity, particularly in light of 
      suppressive mechanisms within tumors. Bypassing suppressive pathways or directly 
      activating DCs can unleash a T-cell response, and although clinical efficacy has 
      proven elusive, therapeutic targeting of DCs continues to hold translational 
      potential in combinatorial approaches.
CI  - Copyright A(c) 2016 Elsevier Ltd. All rights reserved.
FAU - Gardner, Alycia
AU  - Gardner A
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, 
      Tampa, FL, USA; Cancer Biology PhD Program, University of South Florida, Tampa, 
      FL, USA.
FAU - Ruffell, Brian
AU  - Ruffell B
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, 
      Tampa, FL, USA; Breast Oncology, H. Lee Moffitt Cancer Center and Research 
      Institute, Tampa, FL, USA. Electronic address: Brian.Ruffell@moffitt.org.
LA  - eng
GR  - R00 CA185325/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20161025
PL  - England
TA  - Trends Immunol
JT  - Trends in immunology
JID - 100966032
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - *Antigen Presentation
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/*immunology
MH  - Cell Differentiation
MH  - *Cross-Priming
MH  - Dendritic Cells/*immunology/transplantation
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Neoplasms/*immunology/therapy
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Microenvironment
PMC - PMC5135568
MID - NIHMS820674
OTO - NOTNLM
OT  - antigen presentation
OT  - cancer
OT  - dendritic cells
OT  - immunotherapy
OT  - tumor microenvironment
OT  - vaccination
EDAT- 2016/10/30 06:00
MHDA- 2017/09/16 06:00
PMCR- 2017/12/01
CRDT- 2016/10/30 06:00
PHST- 2016/08/05 00:00 [received]
PHST- 2016/09/23 00:00 [revised]
PHST- 2016/09/27 00:00 [accepted]
PHST- 2016/10/30 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
PHST- 2016/10/30 06:00 [entrez]
PHST- 2017/12/01 00:00 [pmc-release]
AID - S1471-4906(16)30140-5 [pii]
AID - 10.1016/j.it.2016.09.006 [doi]
PST - ppublish
SO  - Trends Immunol. 2016 Dec;37(12):855-865. doi: 10.1016/j.it.2016.09.006. Epub 2016 
      Oct 25.